Barinthus Biotherapeutics plc. 8K

Barinthus Biotherapeutics reported Q2 2026 results, advanced its VTP-1000 celiac disease program, obtained additional time from Nasdaq to regain bid-price compliance, and continued toward a planned merger with Clywedog Therapeutics expected to close in the second half of 2026, after which the combined company will be renamed and trade as CLYD with an expected cash runway through 2027.

Barinthus Biotherapeutics plc reported its second quarter 2026 financial results, highlighted by a cash balance of $59.6 million and a quarterly net loss attributable to shareholders of $10.6 million, while advancing corporate initiatives including completion of enrollment in the multiple ascending dose portion of its Phase 1 AVALON trial of VTP-1000 for celiac disease and progressing a proposed merger with Clywedog Therapeutics Inc. that is expected to close in the second half of 2026. The company also received an extension from Nasdaq until December 28, 2026 to regain compliance with the minimum bid price requirement, which coincided with the transfer of its ADS listing from the Nasdaq Global Market to the Nasdaq Capital Market, and indicated that the combined post-merger company will be renamed Clywedog Therapeutics Holdings, Inc., trade under the ticker “CLYD,” and is expected to have a cash runway extending through 2027 supported by existing cash and new investments from OrbiMed, Torrey Pines Investments, LLC and new investors. Operationally, Barinthus Bio increased R&D spending modestly quarter-on-quarter to $3.9 million as it shifted resources toward its I&I-focused lead asset VTP-1000 and away from legacy infectious disease and oncology programs, while general and administrative expenses rose significantly to $7.1 million due mainly to foreign exchange losses and higher professional fees, reflecting increased transaction and corporate activity tied to the proposed combination and listing matters.

Filing Facts

CIK

1828185

Ticker

-

Form

8K

Source Type

sec

Accession

0001628280-26-053940

Alert Tier

7